Pembrolizumab - Biologic Drug Details

Summary for pembrolizumab

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for pembrolizumab

Recent Clinical Trials for pembrolizumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Exelixis	PHASE2
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	PHASE2
Andrew Hantel, MD	PHASE1

See all pembrolizumab clinical trials

Pharmacology for pembrolizumab

Mechanism of Action	Programmed Death Receptor-1-directed Antibody Interactions
Established Pharmacologic Class	Programmed Death Receptor-1 Blocking Antibody

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for pembrolizumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for pembrolizumab Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514	10,934,356	2038-09-27	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514	11,117,961	2037-11-13	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514	11,325,974	2040-12-22	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514	11,325,975	2040-12-22	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514	11,339,219	2040-12-22	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514	11,591,393	2041-09-02	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514	11,629,187	2041-06-22	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for pembrolizumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514	10,001,483	2036-06-24	Patent claims search
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514	10,004,812	2035-02-04	Patent claims search
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514	10,017,492	2035-08-27	Patent claims search
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514	10,092,645	2035-06-16	Patent claims search
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514	10,100,034	2037-07-25	Patent claims search
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514	10,106,546	2037-03-27	Patent claims search
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514	10,111,900	2036-12-21	Patent claims search

International Patents for pembrolizumab

Country	Patent Number	Estimated Expiration
Australia	2015346295
Australia	2019201671
Australia	2021202086
Canada	2966660
China	106999582
China	113694193
European Patent Office	3218004

Supplementary Protection Certificates for pembrolizumab

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
122016000004	Germany		PRODUCT NAME: PEMBROLIZUMAB; REGISTRATION NO/DATE: EU/1/15/1024/001 20150717
CR 2015 00075	Denmark		PRODUCT NAME: PEMBROLIZUMAB; REG. NO/DATE: EU/1/15/1024 20150721
2015/069	Ireland		PRODUCT NAME: PEMBROLIZUMAB; NAT REGISTRATION NO/DATE: EU/1/15/1024/001 20150717; FIRST REGISTRATION NO/DATE: EU/1/15/1024/001 17/07/2015 20260325
15C0097	France		PRODUCT NAME: LE PEMBROLIZUMAB; REGISTRATION NO/DATE: EU/1/15/1024 20150721
PA2016001	Lithuania		PRODUCT NAME: PEMBROLIZUMABAS; REGISTRATION NO/DATE: EU/1/15/1024/001 20150717
CR 2016 00001	Denmark		PRODUCT NAME: PEMBROLIZUMAB; REG. NO/DATE: EU/1/15/1024 20150721
CA 2016 00001	Denmark		PRODUCT NAME: PEMBROLIZUMAB; REG. NO/DATE: EU/1/15/1024 20150721

Pembrolizumab Market Dynamics and Financial Trajectory (Key Exclusivity, Pricing, Competition, and Revenue Outlook)

Last updated: July 22, 2026

Pembrolizumab (Keytruda) is in a mature, high-volume oncology biologics market driven by first-line use expansion, combination regimens, and label broadening, offset by patent expiry mechanics for older indications, ongoing biosimilar entry pressure in selected geographies, and dose intensity management. Financial trajectory remains resilient but shifts toward higher share of combination use, new line-of-therapy adoption, and mix changes across PD-1 monotherapy versus PD-1 regimens. The market is also shaped by payer utilization controls, site-of-care economics, and the cannibalization risk from next-generation PD-1/PD-L1 antibodies and next-line sequencing strategies.

What is the current commercial performance trajectory for pembrolizumab Keytruda?

Keytruda revenue has scaled with sustained uptake across multiple tumor types and line settings, with growth increasingly driven by combination therapy adoption, expanded indications, and geographic rollout. Over time, the growth rate typically decelerates as markets mature and as competition rises, but absolute revenue remains supported by ongoing label expansions and broad clinical adoption.

How do pembrolizumab revenue drivers differ by line of therapy?

• First-line settings: Growth lever is regimen expansion and approvals that place PD-1 earlier, increasing eligible patient pools.
• Second-line and later: Growth is supported by persistence of durable responders, but growth is more sensitive to treatment sequencing and competitor penetration.
• Combination regimens: Higher WAC exposure per patient but can face payer scrutiny tied to comparative value versus alternatives.

What is the price-and-mix impact on pembrolizumab financial trajectory?

• Mix shift: Revenue mix tends to shift toward higher-cost combinations as they gain share.
• Net pricing pressure: Rebates and contracting typically rise over time, and as indication-level competition increases.
• Utilization management: Dose timing and schedule adherence can become cost-control levers for payers.

How do market dynamics shape pembrolizumab demand across oncology segments?

Pembrolizumab demand is segmented by:

• Tumor type: Lung, melanoma, head-and-neck, urothelial, GI, lymphoma, and MSI-high settings.
• Biomarker status: PD-L1 expression, MSI-H/dMMR, TMB-high, and other tumor-agnostic proxies.
• Combination versus monotherapy: Combination use increases total treated patient counts but raises regimen economics.

Which tumor categories are most economically material for Keytruda?

Keytruda’s economic core has historically concentrated in high-incidence and recurrently treated segments including:

• Non-small cell lung cancer (NSCLC) across PD-L1 strata and combination strategies
• Melanoma
• Head and neck squamous cell carcinoma (HNSCC)
• Urothelial carcinoma
• Gastroesophageal and other GI settings
• MSI-H/dMMR tumors across multiple organ systems

How do biomarker strategies change the competitive landscape?

• PD-L1 testing infrastructure supports patient identification and enables plan-level contracting strategies by subgroup.
• MSI-H/dMMR tumor-agnostic utilization is comparatively less dependent on PD-L1 assays, supporting more stable uptake where the biomarker is prevalent.

What are the key patent and exclusivity timelines affecting pembrolizumab in the US?

The US commercial timeline for pembrolizumab is shaped by biologic exclusivity, method/formulation and formulation-process patents, and jurisdiction-by-jurisdiction exclusivity for particular product/indication scopes. Since the core product is a biologic with complex protection, the practical generics and biosimilars pathway is determined by:

• BLA reference product exclusivity for the reference biologic (12 years)
• Potential 6-month exclusivity extensions for pediatric investigation plan outcomes or other qualifying pediatric data (if applicable)
• Patent challenge mechanics under the BPCIA: litigation timing and settlement terms that dictate effective entry dates.

What patents protect pembrolizumab, and how do they affect biosimilar entry?

For biologics, protection includes:

• Composition-of-matter and antibody variants (where applicable)
• Manufacturing and process patents
• Formulation and delivery patents
• Method-of-use patents that cover specific dosing regimens, lines of therapy, or combinations

When does US exclusivity typically expire for pembrolizumab?

For US regulatory exclusivity, the governing framework is reference product exclusivity plus potential extensions, then patent litigation and biosimilar application approval pathways under the BPCIA.

Because the exact expiration date for exclusivity and the exact set of enforceable patents depend on the Orange Book and the BLA license history, the only robust, business-usable conclusion is:

• Biosimilar launch timing is usually delayed by patent thickets and settlements even after exclusivity windows close.

What is the Orange Book status of pembrolizumab, and how does it translate to generic risk?

Pembrolizumab is a biologic and is not evaluated under the conventional “Orange Book small-molecule” patent listing framework for generics. Instead, key protection for biosimilar entry relies on:

• BPCIA patent listings/notice-of-CHALLENGE procedures
• District court litigation over listed patents
• FDA approval status for biosimilar licensing

The business implication is:

• Generic risk is not the conventional ANDA scenario; the risk is biosimilar competition governed by biosimilar designation and interchangeability rules where pursued.

How many biosimilar candidates exist for pembrolizumab, and where is real-world entry risk highest?

Biosimilar entry risk depends on:

• Jurisdictional approvals (FDA/EMA first, then local approvals)
• Patent settlement outcomes
• Manufacturing readiness and supply scale
• Interchangeability and formulary adoption

Which geographies matter most for financial exposure?

• US: Higher financial exposure due to large reimbursement markets and high-value contracting.
• EU and UK: Revenue impact depends on national formulary adoption and tender mechanisms.
• Canada, Japan, and select APAC markets: Entry can occur earlier or later based on local regulatory and patent status.

What biosimilar adoption patterns tend to do to pricing?

• Initial launch: Lower uptake until pharmacy benefit managers broaden coverage.
• Second wave: Price erosion accelerates when multiple biosimilars compete.
• Net effect: Revenue decline can be partial and concentrated by indication and payer segment.

How does competitive pressure from other PD-1/PD-L1 antibodies affect pembrolizumab revenue?

Competition is not limited to biosimilars of pembrolizumab. It includes:

• Other PD-1/PD-L1 antibodies with different trial evidence, dosing schedules, and biomarker positioning.
• Combination regimen exclusivity in certain indications due to trial outcomes.
• Next-generation checkpoint approaches that can displace PD-1 in some lines.

How does treatment sequencing change Keytruda’s share?

In metastatic oncology, PD-1 therapies often trade off with:

• Anti-CTLA-4
• TKI combinations in EGFR/ALK contexts
• Antibody-drug conjugates and other post-progression options
• CAR T and bispecifics in some hematologic disease lines

Share shifts depend on clinical guideline adoption and payer preferences.

What formulation and dosing factors drive pembrolizumab market access economics?

Payer and provider economics for IV biologics often hinge on:

• Infusion time and chair utilization
• Dose per cycle and schedule
• Waste management and vials utilization
• Therapeutic equivalence in contracting

How does regimen choice influence total cost of therapy?

• Combination regimens increase total infusion counts and monitoring.
• Shorter infusion times or optimized administration protocols can reduce operational friction, indirectly supporting utilization.

Which clinical and label changes are most likely to sustain pembrolizumab demand?

Demand resilience typically tracks with:

• Expansion in earlier lines
• Broader biomarker-aligned approvals
• More durable data and subgroup confirmation
• Improved combination tolerability enabling regimen persistence

What label expansion patterns correlate with sales resilience in PD-1 agents?

• Approvals that add large patient pools in common tumor types.
• Approvals that enable combination regimens in settings where historically standard-of-care alternatives exist.
• Indications that are less sensitive to PD-L1 stratification.

What patent litigation and settlement dynamics historically affect pembrolizumab biosimilar timing?

For biosimilars, the dominant commercial determinant is not merely the presence of patents but:

• The breadth of method-of-use and manufacturing process patents
• Settlement design including launch dates, exclusivity “carve-outs,” and switching protections
• Procedural timing (stay durations, appeal paths, and district court schedules)

How do settlements translate into commercial outcomes?

• Delayed launch: Keeps price higher for longer.
• Limited launch scope: Restricts initial biosimilar use to some indications or dosing.
• Switching protections: Slows payer formulary switches, reducing immediate market share loss.

What generic or biosimilar entry scenarios are most material for pembrolizumab revenue?

Business scenarios typically cluster around:

1. Single biosimilar entry in a major market: moderate price erosion, slower share shift.
2. Multi-biosimilar competition: accelerated discounts and higher formulary turnover.
3. Therapeutic substitution bottlenecks: limited uptake due to non-interchangeable status or provider caution.
4. Payer contracting strategies: step-therapy, prior authorization, and indication-level exclusions.

Which revenue lines are most sensitive to biosimilar substitution?

• High-volume indications where plan-level substitution is practical.
• Hospital and community oncology settings with standardized ordering and infusion protocols.
• Formulary-controlled segments where switching is contractually enabled.

How does pembrolizumab compare with competing PD-1 biologics on market dynamics?

Key competitive differentiators that influence share are:

• Line-of-therapy adoption driven by trial endpoints and guideline inclusion
• Tolerability and treatment durability profiles that affect physician preference
• Contracting and managed-care arrangements, including bundle discounts for combination therapies

In general, the PD-1 class is characterized by:

• High switching volatility when multiple agents have comparable efficacy
• Contract-driven share as formularies seek lower net acquisition cost
• Sequential therapy effects that can blunt uptake in later lines

How does reimbursement and payer behavior influence Keytruda’s net revenue path?

Net revenue for high-cost biologics is governed by:

• Commercial rebate structures
• Medicare and Medicaid contracting
• Value-based arrangements
• Prior authorization requirements

What payer levers most often reduce effective pembrolizumab utilization?

• Step edits requiring prior use of another therapy
• Denials in low-biomarker or low-probability responder subgroups
• Treatment duration caps without confirmatory disease response

How strong is the long-term patent estate for pembrolizumab versus biosimilar pressures?

The practical measure of patent estate strength is:

• Whether key enforceable patents cover manufacturing and method-of-use features
• How many patents remain litigated near the window for biosimilar approval
• Settlement outcomes that can limit or delay entry

The market-level conclusion for pembrolizumab is that:

• Patent and settlement mechanics generally maintain a time buffer for biosimilar entry even after biologic exclusivity windows close, especially in high-revenue indications.

Key Takeaways

• Pembrolizumab’s financial trajectory remains supported by broad oncology applicability, label expansion, and sustained durability in responsive populations, with growth increasingly driven by combination regimens and mix shift.
• Market dynamics increasingly reflect payer utilization management, dose intensity and operational economics, and competitive displacement by other PD-1/PD-L1 agents and novel modalities.
• Biosimilar risk is structurally different from small-molecule generics and is driven by BPCIA patent litigation and settlements more than by conventional “Orange Book” expiry mechanics.
• Revenue sensitivity is highest in high-volume indications where payer switching is feasible and where multiple biosimilar competitors can compress net prices quickly.

FAQs

1. What line-of-therapy expansions most increase pembrolizumab eligible patient pools?
2. How do biosimilar settlements typically affect the timing of pembrolizumab market share loss?
3. Which payer controls most directly reduce pembrolizumab net utilization in oncology formularies?
4. How does pembrolizumab pricing erosion differ in the US versus EU tender and contracting environments?
5. What patient biomarker strategies (PD-L1, MSI-H/dMMR) drive pembrolizumab demand stability?

References (APA)

1. FDA. (n.d.). BLA approval and biosimilar pathways. US Food and Drug Administration.
2. FDA. (n.d.). Biologics Price Competition and Innovation Act (BPCIA) framework. US Food and Drug Administration.
3. European Medicines Agency. (n.d.). Overview of biosimilar assessment and authorization. European Medicines Agency.